Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Lifestyle interventions are the foundation of treatment in newly diagnosed type 2 diabetes. However, their therapeutic potential in advanced disease stages is unknown. We evaluated the efficacy of the Telemedical Lifestyle intervention Program (TeLiPro) in improving metabolic control in advanced-stage type 2 diabetes. RESEARCH DESIGN AND METHODS: In this single-blind, active comparator, intervention study, patients with type 2 diabetes (with glycated hemoglobin [HbA1c] ≥7.5% [58.5 mmol/mol]), and BMI ≥27 kg/m2 and on ≥2 antidiabetes medications) were recruited in Germany and randomized 1:1 using an electronically generated random list and sealed envelopes into two parallel groups. The data analyst was blinded after assignment. The control group (n = 100) got weighing scales and step counters and remained in routine care. The TeLiPro group (n = 102) additionally received telemedical coaching including medical-mental motivation, a formula diet, and self-monitored blood glucose for 12 weeks. The primary end point was the estimated treatment difference in HbA1c reduction after 12 weeks. All available values per patient (n = 202) were analyzed. Analyses were also performed at 26 and 52 weeks of follow-up. RESULTS: HbA1c reduction was significantly higher in the TeLiPro group (mean ± SD −1.1 ± 1.2% vs. −0.2 ± 0.8%; P < 0.0001). The estimated treatment difference in the fully adjusted model was 0.8% (95% CI 1.1; 0.5) (P < 0.0001). Treatment superiority of TeLiPro was maintained during follow-up (week 26: 0.6% [95% CI 1.0; 0.3], P = 0.0001; week 52: 0.6% [0.9; 0.2], P < 0.001). The same applies for secondary outcomes: weight (TeLiPro −6.2 ± 4.6 kg vs. control −1.0 ± 3.4 kg), BMI (−2.1 ± 1.5 kg/m2 vs. −0.3 ± 1.1 kg/m2), systolic blood pressure (−5.7 ± 15.3 mmHg vs. −1.6 ± 13.8 mmHg), 10-year cardiovascular disease risk, antidiabetes medication, and quality of life and eating behavior (P < 0.01 for all). The effects were maintained long-term. No adverse events were reported. CONCLUSIONS: In advanced-stage type 2 diabetes, TeLiPro can improve glycemic control and may offer new options to avoid pharmacological intensification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“During the prediabetes stages, lifestyle interventions can prevent or delay the development of the disease (1,2).”
BackgroundGeneral Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491 · cited 3×
“Ten-year CVD risk was assessed according to Framingham Risk Score (16).”
InfluentialThe three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger
Stunkard, A. J., & Messick, S. (1985) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(85)90010-8 · Cited by 4,687
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., Bullinger, M., Kaasa, S., Leplege, A., Prieto, L., et al. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00109-7 · Cited by 2,907
Lorig, K. R., Sobel, D. S., Stewart, A. L., Brown, B. W., Bandura, A., Ritter, P., Gonzalez, V. M., Laurent, D. D., & Holman, H. R. (1999) · Medical Care · doi:10.1097/00005650-199901000-00003 · Cited by 2,261
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Gloy, V. L., Briel, M., Bhatt, D. L., Kashyap, S. R., Schauer, P. R., Mingrone, G., Bucher, H. C., & Nordmann, A. J. (2013) · BMJ · doi:10.1136/bmj.f5934 · Cited by 1,351 · cited 1×
“The speed of the glucose-lowering effect using the TeLiPro approach was comparable with that observed after bariatric surgery (25).”
ResultMingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Nanni, G., Castagneto, M., Bornstein, S., & Rubino, F. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00075-6 · Cited by 1,220
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
(2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.334 · Cited by 1,162
Online Diabetes Self-Management Program
Lorig, K., Ritter, P. L., Laurent, D. D., Plant, K., Green, M., Jernigan, V. B. B., & Case, S. (2010) · Diabetes Care · doi:10.2337/dc09-2153 · Cited by 316
Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259
Spanish Diabetes Self-Management With and Without Automated Telephone Reinforcement
Lorig, K., Ritter, P. L., Villa, F., & Piette, J. D. (2008) · Diabetes Care · doi:10.2337/dc07-1313 · Cited by 255
Buysman, E. K., Liu, F., Hammer, M., & Langer, J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0199-z · Cited by 101 · cited 2×
“The annual drug cost for GLP-1 receptor agonist therapies is between $1,765 and $6,338 (22,23).”
BackgroundKempf, K., Tankova, T., & Martin, S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0213 · Cited by 40
Self-citation
Research works printed but not linked: 12
- Esposito, 2009, Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial, Ann Intern Med, 151, 306, 10.7326/0003-4819-151-5-200909010-00004 · DOI · Paper page
- Gregg, 2012, Association of an intensive lifestyle intervention with remission of type 2 diabetes, JAMA, 308, 2489, 10.1001/jama.2012.67929 · DOI · Paper page
- UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
- Kempf, 2014, Meal replacement reduces insulin requirement, HbA1c and weight long-term in type 2 diabetes patients with >100 U insulin per day, J Hum Nutr Diet, 27, 21, 10.1111/jhn.12145 · DOI
- Kempf, 2012, The Da Vinci Medical-mental motivation program for supporting lifestyle changes in patients with type 2 diabetes, Dtsch Med Wochenschr, 137, 362
- Mayer, 2014, Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes, Diabetes Obes Metab, 16, 90, 10.1111/dom.12191 · DOI · Paper page
- Lage, 2009, Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy, Adv Ther, 26, 217, 10.1007/s12325-009-0002-0 · DOI
- Lasa, 2014, Comparative effect of two Mediterranean diets versus a low-fat diet on glycaemic control in individuals with type 2 diabetes, Eur J Clin Nutr, 68, 767, 10.1038/ejcn.2014.1 · DOI · Paper page
- Welch, 2015, An internet-based diabetes management platform improves team care and outcomes in an urban Latino population, Diabetes Care, 38, 561, 10.2337/dc14-1412 · DOI · Paper page
- O’Connor, 2014, Randomized trial of telephone outreach to improve medication adherence and metabolic control in adults with diabetes, Diabetes Care, 37, 3317, 10.2337/dc14-0596 · DOI · Paper page
- Lorig, 2013, Effectiveness of a generic chronic disease self-management program for people with type 2 diabetes: a translation study, Diabetes Educ, 39, 655, 10.1177/0145721713492567 · DOI
- Lorig, 2009, Community-based peer-led diabetes self-management: a randomized trial, Diabetes Educ, 35, 641, 10.1177/0145721709335006 · DOI · Paper page
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Han, H., Cao, Y., Feng, C., Zheng, Y., Dhana, K., Zhu, S., Shang, C., Yuan, C., & Zong, G. (2022) · Diabetes Care · doi:10.2337/dc21-1512 · Cited by 290
Lifestyle interventions in nonalcoholic fatty liver disease
Younossi, Z. M., Zelber-Sagi, S., Henry, L., & Gerber, L. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00800-4 · Cited by 281
Mao, Y., Lin, W., Wen, J., & Chen, G. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001225 · Cited by 108
Metadata
- Authors
- Kempf, K., Altpeter, B., Berger, J., Reuß, O., Fuchs, M., Schneider, M., Gärtner, B., Niedermeier, K., & Martin, S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-06-13
- Volume
- 40
- Issue
- 7
- Pages
- 863-871
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2613929840
- Cited by
- 159
- References
- 17
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Boehringer Ingelheim International GmbH
- Gesellschaft von Freunden und Förderern der Heinrich-Heine-Universität Düsseldorf e.V.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.